within Pharmacolibrary.Drugs.ATC.J;

model J05AP57
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.47,
    Cl             = 0.25,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.044,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.014666666666666666,
    Tlag           = 30.0
  );

  annotation(Documentation(
    info ="<html><body><p>Glecaprevir and pibrentasvir is a fixed-dose combination antiviral medication used for the treatment of chronic hepatitis C virus (HCV) infection in adults and children. It acts as a direct-acting antiviral by inhibiting HCV NS3/4A protease (glecaprevir) and NS5A (pibrentasvir). The combination is approved worldwide for treating all major HCV genotypes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data in healthy adults and HCV-infected patients; mixed-sex adult population. Parameters are for steady-state after multiple oral doses of 300 mg glecaprevir / 120 mg pibrentasvir once daily.</p><h4>References</h4><ol><li><p>Flamm, S, et al., &amp; Mensa, FJ (2019). Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection. <i>Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association</i> 17(3) 527–535.e6. DOI:<a href=&quot;https://doi.org/10.1016/j.cgh.2018.07.003&quot;>10.1016/j.cgh.2018.07.003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30012435/&quot;>https://pubmed.ncbi.nlm.nih.gov/30012435</a></p></li><li><p>Lin, CW, et al., &amp; Liu, W (2017). Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects. <i>Journal of clinical pharmacology</i> 57(12) 1616–1624. DOI:<a href=&quot;https://doi.org/10.1002/jcph.959&quot;>10.1002/jcph.959</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28800195/&quot;>https://pubmed.ncbi.nlm.nih.gov/28800195</a></p></li><li><p>Kosloski, MP, et al., &amp; Liu, W (2023). Characterizing complex and competing drug-drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine. <i>Clinical and translational science</i> 16(4) 593–605. DOI:<a href=&quot;https://doi.org/10.1111/cts.13471&quot;>10.1111/cts.13471</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36597378/&quot;>https://pubmed.ncbi.nlm.nih.gov/36597378</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AP57;
